Drug Trial Radar · NCT00828737
Safety of Gadovist in Renally Impaired Patients
Last checked: Nov 19, 2026Latest source record: Feb 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
927
Actual
Start
Dec 2008
Primary completion
Jan 2015
Study completion Jan 2015
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jan 26, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Gadovist, will be asked to participate. The administration of contrast agents that contain gadolinium such as Gadovist might increase a potential risk to develop a rare condition called nephrogenic systemic fibrosis (NSF) in patients with renal impairment. This study is to assess the potential risk to develop NSF in patients with renal impairment after the administration of Gadovist. Patients who are enrolled in this study will receive a Gadovist enhanced MRI scan which was prescribed by the referring doctor. After the MRI scan the patient will be included in a two year follow-up period to assess if signs or symptoms suggestive of NSF have appeared.
Conditions
- Fibrosis
- Renal Impairment
Interventions
Gadobutrol (Gadovist, BAY86-4875)Drug
Gadovist in approved indications at approved dosages
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with moderate to severe renal impairment, who develop Nephrogenic Systemic Fibrosis (NSF), based on diagnostically specific clinical and histopathological informationTime frame: From the time of MRI until the end of follow-up period (24 months)
Locations
70 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Westmead NSW, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Clayton, Victoria, Australia
Site not named
Geelong, Victoria, Australia
Site not named
Ehenbichl, Austria
Site not named
Graz, Austria
Site not named
Leoben, Austria
Site not named
Vienna, Austria
Site not named
Vienna, Austria
Site not named
Innsbruck, Tyrol, Austria
Site not named
Calgary, Alberta, Canada
Site not named
Hamilton, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Fleurimont, Quebec, Canada
Site not named
Le Kremlin-Bicêtre, France
Site not named
Lille, France
Site not named
Marseille, France
Site not named
Paris, France
Site not named
Reims, France
Site not named
Mannheim, Baden-Wurttemberg, Germany
Site not named
Tübingen, Baden-Wurttemberg, Germany
Site not named
Coburg, Bavaria, Germany
Site not named
Erlangen, Bavaria, Germany
Site not named
München, Bavaria, Germany
Site not named
Regensburg, Bavaria, Germany
Site not named
Neuruppin, Brandenburg, Germany
Site not named
Hamburg, Free and Hanseatic City of Hamburg, Germany
Site not named
Frankfurt am Main, Hesse, Germany
Site not named
Hannoversch Münden, Lower Saxony, Germany
Site not named
Osnabrück, Lower Saxony, Germany
Site not named
Dortmund, North Rhine-Westphalia, Germany
Site not named
Essen, North Rhine-Westphalia, Germany
Site not named
Lüdenscheid, North Rhine-Westphalia, Germany
Site not named
Dresden, Saxony, Germany
Site not named
Leipzig, Saxony, Germany
Site not named
Magdeburg, Saxony-Anhalt, Germany
Site not named
Berlin, State of Berlin, Germany
Site not named
Berlin, State of Berlin, Germany
Site not named
Gera, Thuringia, Germany
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.